Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate
the safety and tolerability of MAX-40279-01 in patients with Relapsed or Refractory AML.